Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Mar 23;11(3):e044230.
doi: 10.1136/bmjopen-2020-044230.

Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study

Affiliations
Observational Study

Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study

Caroline Krüger et al. BMJ Open. .

Abstract

Objectives: The aims of our study were to examine the anticholinergic drug use and to assess the association between anticholinergic burden and cognitive function in the multimorbid elderly patients of the MultiCare cohort.

Setting: MultiCare was conducted as a longitudinal cohort study in primary care, located in eight different study centres in Germany.

Participants: 3189 patients (59.3% female).

Primary and secondary outcome measures: Baseline data were used for the following analyses. Drugs were classified according to the well-established anticholinergic drug scale (ADS) and the recently published German anticholinergic burden (German ACB). Cognitive function was measured using a letter digit substitution test (LDST) and a mixed-effect multivariate linear regression was performed to calculate the influence of anticholinergic burden on the cognitive function.

Results: Patients used 1764 anticholinergic drugs according to ADS and 2750 anticholinergics according to the German ACB score (prevalence 38.4% and 53.7%, respectively). The mean ADS score was 0.8 (±1.3), and the mean German ACB score was 1.2 (±1.6) per patient. The most common ADS anticholinergic was furosemide (5.8%) and the most common ACB anticholinergic was metformin (13.7%). The majority of the identified anticholinergics were drugs with low anticholinergic potential: 80.2% (ADS) and 73.4% (ACB), respectively. An increasing ADS and German ACB score was associated with reduced cognitive function according to the LDST (-0.26; p=0.008 and -0.24; p=0.003, respectively).

Conclusion: Multimorbid elderly patients are in a high risk for using anticholinergic drugs according to ADS and German ACB score. We especially need to gain greater awareness for the contribution of drugs with low anticholinergic potential from the cardiovascular system. As anticholinergic drug use is associated with reduced cognitive function in multimorbid elderly patients, the importance of rational prescribing and also deprescribing needs to be further evaluated.

Trial registration number: ISRCTN89818205.

Keywords: clinical pharmacology; epidemiology; primary care.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Kernal density estimator for the baseline assessment of the letter digit substitution test with the purpose of measuring the cognitive function of patients and the number of boxes patients were able to fill out correctly in a defined time. LDST, letter digit substitution test.

Similar articles

Cited by

References

    1. van den Akker M, Vaes B, Goderis G, et al. . Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015. PLoS One 2019;14:e0212046. 10.1371/journal.pone.0212046 - DOI - PMC - PubMed
    1. Lee EA, Brettler JW, Kanter MH. Refining the definition of polypharmacy and its link to disability in older adults: conceptualizing necessary polypharmacy, unnecessary polypharmacy, and polypharmacy of unclear benefit. Perm J 2020;2410.7812/TPP/18.212 - DOI - PMC - PubMed
    1. Villalba-Moreno Angela M, Alfaro-Lara ER, Rodríguez-Pérez A, et al. . Association between drug burden index and functional and cognitive function in patients with multimorbidity. Curr Pharm Des 2018;24:3384–91. 10.2174/1381612824666180327154239 - DOI - PubMed
    1. De Vreese LP, Mantesso U, De Bastiani E, et al. . Anticholinergic burden in adult and elderly people with intellectual disabilities: results from an Italian multicenter cross-sectional study. PLoS One 2018;13:e0205897. 10.1371/journal.pone.0205897 - DOI - PMC - PubMed
    1. Ps N, Ms S, Sn H. Anticholinergics: theoretical and clinical overview [online]. Expert Opin Drug Saf 2016. - PubMed

Publication types

Substances

Associated data